twoXAR, Santen deal
Santen's Santen Inc. subsidiary partnered with artificial intelligence company twoXAR to discover candidates to treat glaucoma. The deal marks the AI company’s move from a service model, as twoXAR said the company will also be engaged as a co-development partner. twoXAR uses its DUMA technology to reduce the time and money spent synthesizing and screening thousands of potential drug candidates. twoXAR said the company is expanding from a service model to "acting more like a traditional pharma company," emphasizing that its AI platform can be used to lead drug discovery rather than confirm existing hypotheses. twoXAR declined to disclose financial details of the deal. Santen will have exclusive rights to any compounds produced in the partnership...